Financial Results Third Quarter2023 2 This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "assume," "may," "will," "likely," "potential," "projects," "predicts," "continue," "goal," ...

Financial Performance - Revenue for Q3 2023 reached $226.7 million, a 56.5% increase from $144.8 million in Q3 2022[20] - Gross profit for Q3 2023 was $187.3 million, compared to $114.5 million in Q3 2022, reflecting a 63.5% increase[20] - Total operating expenses for Q3 2023 were $195.9 million, up from $134.4 million in Q3 2022, representing a 45.7% increase[20] - Net loss for Q3 2023 was $7.6 million, an improvement from a net loss of $18.8 million in Q3 2022[20] - Revenue for the nine months ended September 30, 2023, was $625.4 million, compared to $359.7 million for the same period in 2022[138] - Adjusted EBITDA for Q3 2023 was $12.25 million, compared to a loss of $6.1 million in Q3 2022[138] - Adjusted EBITDA margin for Q3 2023 was 5%, improving from a negative margin of 4% in Q3 2022[138] Cash and Assets - Cash and cash equivalents increased to $58.0 million as of September 30, 2023, up from $46.8 million at the end of 2022[18] - Total assets grew to $413.9 million as of September 30, 2023, compared to $366.3 million at the end of 2022[18] - Total stockholders' equity increased to $328.6 million as of September 30, 2023, from $311.7 million at the end of 2022[18] - The total cash, cash equivalents, and restricted cash at the end of the period was $58,852 thousand, slightly up from $58,820 thousand at the end of September 2022[27] - The company had total short-term investments of $154.5 million as of September 30, 2023, compared to $132.9 million as of December 31, 2022[56] Expenses - Marketing expenses for Q3 2023 were $116.1 million, a 48.0% increase from $78.5 million in Q3 2022[20] - Customer acquisition costs reached $98.6 million in Q3 2023, compared to $67.3 million in Q3 2022, reflecting a strategic investment in marketing[159] - Cost of revenue for Q3 2023 was $39.4 million, a 30% increase from $30.4 million in Q3 2022, primarily due to rising shipping and medical consultation costs[157] - Operations and support expenses rose to $31.6 million in Q3 2023, a 45% increase from $21.8 million in Q3 2022[146] - Technology and development expenses increased to $12.3 million in Q3 2023, a 54% rise from $8.0 million in Q3 2022[147] - General and administrative expenses were $35.9 million in Q3 2023, up 37% from $26.2 million in Q3 2022[149] Subscriber and Revenue Growth - The Company reported 1,426 Subscribers at the end of September 30, 2023, a growth of 510 Subscribers, or 56%, from 916 Subscribers in the same period of 2022[124] - For the three months ended September 30, 2023, the Company generated $219.7 million in Online Revenue, an increase of $79.9 million, or 57%, compared to $139.8 million for the same period in 2022[124] - For the nine months ended September 30, 2023, Online Revenue reached $605.0 million, up $263.7 million, or 77%, from $341.3 million in the same period of 2022[124] - Net Orders for the three months ended September 30, 2023, totaled 2,222, representing an increase of 547 orders, or 33%, from 1,675 in the same period of 2022[124] - Average Order Value (AOV) for the three months ended September 30, 2023, was $99, an increase of $16, or 19%, compared to $83 in the same period of 2022[124] Stock-Based Compensation - Stock-based compensation increased to $48,289 thousand in 2023 from $30,467 thousand in 2022, reflecting a 58.6% rise[27] - The total stock-based compensation expense for the nine months ended September 30, 2023, was $48.3 million, compared to $30.5 million for the same period in 2022, representing a year-over-year increase of 58.7%[100] - The Company recognized stock-based compensation expense of $17.3 million for the three months ended September 30, 2023, compared to $11.0 million for the same period in 2022, indicating a 57.5% increase[100] Future Outlook and Strategy - The company plans to continue investing in fulfillment and operating capabilities, including expanding facilities over the next 12 months[132] - Future growth is expected to come from expanding into new health and wellness categories, requiring financial investments in marketing and operational capabilities[134] - The company emphasizes the importance of customer retention for revenue generation, with a focus on maintaining long-term revenue retention from Subscribers[131] - The company anticipates that marketing initiatives may become increasingly difficult and expensive due to the competitive nature of the market[211] Risks and Challenges - The company has encountered significant risks and uncertainties frequently experienced by new and growing companies in rapidly changing and heavily regulated industries[196] - Evolving government regulations may require increased costs or adversely affect the company's results of operations[197] - The company faces competition from large, well-established healthcare providers and technology companies, which may impact its ability to compete effectively[194] - Negative publicity regarding telehealth and customer confidentiality could limit market acceptance of the company's business model and services[216]

Hims & Hers Health, Inc. (NYSE:HIMS) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President, Investor Relations Andrew Dudum - Co-Founder & Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities Michael Cherny - Bank of America Glen Santangelo - Jefferies Jungwon Kim - Cowen Jonathan Young - Credit Suisse Jailendra Singh - Truist Securities George Hill - De ...

Financials Expand portfolio of strategic partnerships Focus on investments that drive long-term margin expansion potential 2 We have not reconciled forward-looking Adjusted EBITDA or Adjusted EBITDA margin to their most directly comparable U.S. GAAP measures because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For thes ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ____________ HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 001-38986 | 98-1482650 | | --- | --- | --- ...

Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2023 Results Conference Call May 8, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President of Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Jack Wallace - Guggenheim Securities Dan Clark - Bank of America Glen Santangelo - Jefferies Korinne Wolfmeyer - Piper Sandler Luis Mario Higuera - Citi Jailendra Singh - Truist Securities Operator Ladies gentlemen, thank you for standing by ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ____________ HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant (1) has f ...

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates," "expects," "intends," "plans," "may" "will," "likely" "potential," "projects" "predicts" "continue," "goal," "strategy" "future," "forecast" "target" "outlook," ...

Hims & Hers Health, Inc. (NYSE:HIMS) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Alice Lopatto - Vice President of Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Ben Clark - Bank of America Daniel Grosslight - Citi Jack Wallace - Guggenheim Glen Santangelo - Jefferies Jonathan Yong - Credit Suisse Jonna Kim - Cowen George Hill - Deutsche Bank Korinne Wolfmeyer - Piper Sandler Ivan Feinseth - T ...

Telehealth Services and Market Expansion - Hims & Hers has facilitated over 10 million telehealth consultations, providing access to care across all 50 states and the UK[18]. - The company is pursuing rapid category expansion into conditions treatable via telehealth, such as testosterone treatment and weight management, representing significant market opportunities[27][28]. - The company expanded its operations in the UK through the acquisition of Honest Health Limited, enhancing its international presence[30]. - Recent product launches in sexual health and dermatology demonstrate the scalability of the Hims & Hers platform, with plans for additional subscription-based offerings[24]. - The company aims to expand its offerings, including the number and type of products and services, to enhance customer access to telehealth consultations and prescription medications[75]. - The COVID-19 pandemic has increased interest in telehealth solutions, but the sustainability of this interest post-pandemic remains uncertain[123]. - The company faces significant market opportunities as telehealth penetration remains low, indicating potential for growth as consumer behavior shifts[64]. Business Model and Revenue Streams - The company operates on a subscription model, allowing customers to receive products on a recurring basis, which provides predictable revenue streams[22]. - The company’s revenue is primarily driven by subscription-based products and services, and a shift away from this model could adversely affect financial results[95]. - The majority of the company's revenue is derived from customers purchasing subscription-based prescription products and services, which is expected to continue[215]. - Hims & Hers experienced significant revenue growth, increasing from $148.8 million in 2020 to $526.9 million in 2022, representing a growth rate of approximately 253% over two years[104]. Operational Efficiency and Infrastructure - Hims & Hers opened a 300,000 square foot facility in Ohio for dedicated pharmacy services, improving operational efficiency and cost structure[29]. - The company has invested heavily in software and tools to support a remote-first work environment, enhancing its competitive advantage[58]. - The company anticipates continued expansion of operations and headcount, which may strain management and operational infrastructure[105]. - The company relies on relationships with Affiliated Medical Groups for healthcare services, and disruptions in these relationships could adversely affect operations[106]. Compliance and Regulatory Environment - Hims & Hers maintains compliance with extensive healthcare regulations, ensuring the quality and safety of its services and products[36]. - The company has established systems to ensure that affiliated medical groups comply with state licensing laws for telehealth services[40]. - The company does not currently accept payments from third-party payors, limiting exposure to certain healthcare regulations[149]. - The company believes its compounded drug products meet FDA exemption requirements, but risks regulatory actions if deemed non-compliant[48]. - The evolving regulatory landscape may require the company to change its practices, potentially leading to significant initial and ongoing expenses[161]. Marketing and Brand Strategy - More than 80% of first-time customers sought treatment for their conditions for the first time, indicating strong brand awareness and organic growth potential[25]. - The company’s marketing strategy utilizes diverse media channels to maximize brand exposure and prevent overreliance on any single channel[54]. - The marketing team rigorously measures consumer behavior and the effectiveness of marketing budgets to ensure a sufficient return on investment[55]. - The company utilizes social media, emails, text messages, and celebrity influencers as part of its marketing strategy to attract new customers and incentivize existing ones[78]. Employee Engagement and Corporate Culture - As of December 31, 2022, the company employed 651 full-time employees across various functions[57]. - The company launched people manager training and effective communication training in 2022 to enhance employee engagement and satisfaction[59]. - The company emphasizes a growth mindset and uses annual engagement surveys to gather employee feedback for continuous improvement[59]. - The company provides a holistic total rewards package, including medical, dental, vision coverage, and a 401(k) Savings Plan for U.S. employees[61]. Financial Performance and Challenges - The company incurred net losses of $18.1 million, $107.7 million, and $65.7 million for the years ended December 31, 2020, 2021, and 2022, respectively, with an accumulated deficit of $344.6 million as of December 31, 2022[210]. - Historical cash flows from operations were negative for the years ended December 31, 2020, 2021, and 2022, indicating ongoing financial challenges[210]. - The company anticipates increasing expenses in the foreseeable future due to investments in platform growth, provider network expansion, and technological enhancements[210]. - The company may require additional financing in the future, which could be dilutive to stockholders if favorable terms are not available[211]. Risks and Market Competition - The company operates in a highly competitive market with challenges from established healthcare providers and technology companies[72]. - The competitive landscape has intensified due to regulatory changes that lowered barriers to telehealth, potentially allowing new entrants to capture market share more easily[101]. - Negative publicity regarding telehealth and privacy concerns could limit market acceptance of the company’s business model and services[94]. - The company faces challenges related to pricing policies, competition, and the ability to expand treatment options and provider expertise[216]. Data Privacy and Cybersecurity - The company collects consumer data, including email addresses and phone numbers, to enhance marketing efforts, but risks exist regarding data breaches and compliance with privacy laws[81]. - The company is subject to various privacy and data protection laws, including the California Consumer Privacy Act (CCPA) and the General Data Protection Regulation (GDPR), which could impose significant compliance costs and operational changes[180][181]. - The company relies on third-party service providers for critical data management functions, which introduces material cybersecurity risks and potential vulnerabilities to security breaches[185]. - Increased global IT security threats and sophisticated cybercrime pose risks to the confidentiality and integrity of the company's data, potentially leading to significant remediation costs and reputational damage[186][190].